CXCR1 and CXCR2 are G-protein coupled receptors, that have been shown to play 
important role in tumor growth and metastasis, and are prime targets for the 
development of novel therapeutics. Here, we report that targeting CXCR2 and 
CXCR1 activity using orally active small molecule antagonist (SCH-527123, 
SCH-479833) inhibits human colon cancer liver metastasis mediated by decreased 
neovascularization and enhanced malignant cell apoptosis. There were no 
differences in primary tumor growth. These studies demonstrate the important 
role of CXCR2/1 in colon cancer metastasis and that inhibition of CXCR2 and 
CXCR1, small molecule antagonists provides a novel therapeutic strategy.